Professor Brian MacCraith:

Maybe I will start with that and ask Dr. Jessop to give further detail. Obviously, an awful lot depends on what we hear today about the AstraZeneca vaccine and whatever determination the European Medicines Agency comes to in that regard and also whether it makes any comment on the age dimension, a bit like what we have heard from Germany. Absent that, the original plan was certainly that the AstraZeneca vaccine would be used, through the GP network, to address cohort no. 3, which is the over-70s. If for any reason that does not happen, the contingency plan at this stage is to use the Pfizer-BioNTech and Moderna vaccines for that cohort.